THBS3

Summary

THBS3 (thrombospondin 3, HGNC:11787) is a protein-coding gene on chromosome 1q22, encoding Thrombospondin-3 (P49746). Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions.

The protein encoded by this gene belongs to the thrombospondin family. Thrombospondin family members are adhesive glycoproteins that mediate cell-to-cell and cell-to-matrix interactions. This protein forms a pentameric molecule linked by a single disulfide bond. This gene shares a common promoter with metaxin 1. Alternate splicing results in coding and non-coding transcript variants.

Source: NCBI Gene 7059 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 24
• Clinical variants (ClinVar): 142 total
• MANE Select transcript: NM_007112

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11787
Approved symbol	THBS3
Name	thrombospondin 3
Location	1q22
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000169231
Ensembl biotype	protein_coding
OMIM	188062
Entrez	7059

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 11 protein_coding, 3 protein_coding_CDS_not_defined, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000368378, ENST00000428962, ENST00000457183, ENST00000460050, ENST00000465596, ENST00000469769, ENST00000486260, ENST00000496332, ENST00000498500, ENST00000541576, ENST00000541990, ENST00000902272, ENST00000902273, ENST00000902274, ENST00000902275, ENST00000960679, ENST00000960680, ENST00000960681

RefSeq mRNA: 15 — MANE Select: NM_007112 NM_001252607, NM_001252608, NM_001407487, NM_001407488, NM_001407490, NM_001407554, NM_001407555, NM_001407556, NM_001407557, NM_001407558, NM_001407559, NM_001407560, NM_001407561, NM_001407562, NM_007112

CCDS: CCDS1099, CCDS58034, CCDS72937

Canonical transcript exons

ENST00000368378 — 23 exons

Exon	Start	End
ENSE00001741552	155197041	155197213
ENSE00001812852	155207798	155207897
ENSE00003470720	155197463	155197659
ENSE00003475684	155198409	155198602
ENSE00003514041	155199804	155199856
ENSE00003519383	155200897	155201004
ENSE00003519875	155197880	155197928
ENSE00003539715	155195588	155195899
ENSE00003541969	155198042	155198220
ENSE00003543093	155203086	155203137
ENSE00003558747	155201094	155201204
ENSE00003601175	155205060	155205316
ENSE00003607743	155195987	155196126
ENSE00003635284	155206200	155206406
ENSE00003637247	155202812	155202960
ENSE00003650752	155203513	155203539
ENSE00003652041	155202261	155202401
ENSE00003654553	155201417	155201569
ENSE00003664053	155203223	155203305
ENSE00003669305	155201957	155202034
ENSE00003670336	155204855	155204957
ENSE00003715233	155200451	155200610
ENSE00003749035	155199995	155200113

Expression profiles

Bgee: expression breadth ubiquitous, 232 present calls, max score 98.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.7860 / max 294.6470, expressed in 1759 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
14918	7.7303	1239
14919	2.6860	1338
14920	1.3562	821
14917	0.0136	3

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.13	gold quality
tibia	UBERON:0000979	97.73	gold quality
body of uterus	UBERON:0009853	96.64	gold quality
right testis	UBERON:0004534	96.51	gold quality
left testis	UBERON:0004533	96.24	gold quality
right coronary artery	UBERON:0001625	96.00	gold quality
left uterine tube	UBERON:0001303	95.95	gold quality
tibial nerve	UBERON:0001323	95.76	gold quality
tendon of biceps brachii	UBERON:0008188	95.27	gold quality
lower esophagus mucosa	UBERON:0035834	95.12	gold quality
endocervix	UBERON:0000458	95.05	gold quality
ascending aorta	UBERON:0001496	95.02	gold quality
thoracic aorta	UBERON:0001515	94.95	gold quality
descending thoracic aorta	UBERON:0002345	94.91	gold quality
left ovary	UBERON:0002119	94.74	gold quality
right ovary	UBERON:0002118	94.63	gold quality
left coronary artery	UBERON:0001626	94.42	gold quality
adenohypophysis	UBERON:0002196	94.41	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.35	gold quality
lower esophagus	UBERON:0013473	94.33	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.33	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.25	gold quality
mucosa of stomach	UBERON:0001199	94.17	gold quality
coronary artery	UBERON:0001621	93.97	gold quality
aorta	UBERON:0000947	93.84	gold quality
left lobe of thyroid gland	UBERON:0001120	93.78	gold quality
right lobe of thyroid gland	UBERON:0001119	93.58	gold quality
ectocervix	UBERON:0012249	93.50	gold quality
testis	UBERON:0000473	93.40	gold quality
tibial artery	UBERON:0007610	93.15	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.21
E-GEOD-100618	no	324.11

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting THBS3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-183-5P	99.31	72.27	1164
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-887-5P	98.82	65.90	1347
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-4780	98.57	64.75	611
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-6742-3P	97.95	64.50	1490
HSA-MIR-33B-3P	97.92	67.39	529
HSA-MIR-515-3P	97.92	67.98	506
HSA-MIR-519E-3P	97.92	68.25	508
HSA-MIR-1271-3P	97.56	64.85	865
HSA-MIR-550A-3-5P	97.56	65.35	823
HSA-MIR-550A-5P	97.56	65.35	823
HSA-MIR-5187-3P	97.28	67.10	1037
HSA-MIR-1182	96.41	64.89	336
HSA-MIR-8074	90.61	65.46	165

Literature-anchored findings (GeneRIF, showing 6)

• Normal human adult corneal keratocytes have mRNA for this protein. (PMID:11943589)
• This is the first report of the THBS3 gene working as a stimulator of tumor progression. (PMID:17022822)
• Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer. (PMID:33910854)
• Serum levels of the IgA isotype switch factor TGF-beta1 are elevated in patients with COVID-19. (PMID:33961290)
• mRNA Expression of thrombospondin 1, 2 and 3 from proximal to distal in human abdominal aortic aneurysm - preliminary report. (PMID:34669362)
• Hyperuricemia and coronary heart disease: The mediating role of blood pressure and thrombospondin 3. (PMID:37524613)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	thbs3b	ENSDARG00000012060
danio_rerio	thbs3a	ENSDARG00000077641
mus_musculus	Thbs3	ENSMUSG00000028047
rattus_norvegicus	Thbs3	ENSRNOG00000059903
drosophila_melanogaster	Tsp	FBGN0031850

Paralogs (5): ISM1 (ENSG00000101230), COMP (ENSG00000105664), THBS4 (ENSG00000113296), THBS1 (ENSG00000137801), THBS2 (ENSG00000186340)

Protein

Protein identifiers

Thrombospondin-3 — P49746 (reviewed: P49746)

All UniProt accessions (4): P49746, B4DQH6, F5H4Z8, Q2HIZ1

UniProt curated annotations — full annotation on UniProt →

Function. Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Can bind to fibrinogen, fibronectin, laminin and type V collagen.

Subunit / interactions. Oligomer; disulfide-linked.

Similarity. Belongs to the thrombospondin family.

Isoforms (2)

UniProt ID	Names	Canonical?
P49746-1	1	yes
P49746-2	2

RefSeq proteins (15): NP_001239536, NP_001239537, NP_001394416, NP_001394417, NP_001394419, NP_001394483, NP_001394484, NP_001394485, NP_001394486, NP_001394487, NP_001394488, NP_001394489, NP_001394490, NP_001394491, NP_009043* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR003367	Thrombospondin_3-like_rpt	Repeat
IPR008859	Thrombospondin_C	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR017897	Thrombospondin_3_rpt	Repeat
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR024665	TSP/COMP_CC	Domain
IPR028507	TSP3_CC	Domain
IPR028974	TSP_type-3_rpt	Homologous_superfamily
IPR046970	TSP/COMP_CC_sf	Homologous_superfamily
IPR048287	TSPN-like_N	Domain
IPR049883	NOTCH1_EGF-like	Domain

Pfam: PF02412, PF05735, PF07645, PF11598

UniProt features (50 total): disulfide bond 23, repeat 8, domain 5, glycosylation site 4, compositionally biased region 3, region of interest 2, sequence variant 2, signal peptide 1, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49746-F1	85.66	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (23): 266, 269, 278–289, 283–300, 303–314, 320–332, 326–341, 344–368, 374–388, 382–397, 400–412, 418–432, 426–442, 444–455, 471–478, 483–503, 519–539, 542–562, 578–598, 601–621 …

Glycosylation sites (4): 310, 407, 644, 937

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-186797	Signaling by PDGF

MSigDB gene sets: 180 (showing top): GOBP_BONE_TRABECULA_MORPHOGENESIS, GOBP_CARTILAGE_DEVELOPMENT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GCANCTGNY_MYOD_Q6, GOBP_GROWTH, RACCACAR_AML_Q6, SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN, GGGTGGRR_PAX4_03, GOBP_BONE_GROWTH, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_ANATOMICAL_STRUCTURE_MATURATION, CCANNAGRKGGC_UNKNOWN, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_BONE_DEVELOPMENT, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT

GO Biological Process (5): growth plate cartilage development (GO:0003417), cell-matrix adhesion (GO:0007160), ossification involved in bone maturation (GO:0043931), bone trabecula formation (GO:0060346), cell adhesion (GO:0007155)

GO Molecular Function (4): calcium ion binding (GO:0005509), heparin binding (GO:0008201), extracellular matrix structural constituent (GO:0005201), protein binding (GO:0005515)

GO Cellular Component (3): extracellular region (GO:0005576), extracellular matrix (GO:0031012), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Receptor Tyrosine Kinases	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
endochondral bone growth	1
cartilage development involved in endochondral bone morphogenesis	1
connective tissue development	1
cell-substrate adhesion	1
ossification	1
bone maturation	1
skeletal system morphogenesis	1
trabecula formation	1
bone trabecula morphogenesis	1
cellular process	1
metal ion binding	1
glycosaminoglycan binding	1
sulfur compound binding	1
structural molecule activity	1
extracellular matrix	1
binding	1
external encapsulating structure	1
cytoplasm	1

Protein interactions and networks

STRING

1885 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
THBS3	MTX1	Q13505	905
THBS3	TRIM46	Q7Z4K8	904
THBS3	GBA1	P04062	738
THBS3	MUC1	P13931	665
THBS3	COMP	P49747	638
THBS3	AZU1	P20160	590
THBS3	PGK2	P07205	547
THBS3	TNXB	P22105	507
THBS3	ITGA7	Q13683	497
THBS3	ITGA6	P23229	494
THBS3	ITGA5	P08648	492
THBS3	ENTREP3	P81408	478
THBS3	ITGB5	P18084	468
THBS3	COL9A3	Q14050	457
THBS3	THBS4	P35443	432

IntAct

15 interactions, top by confidence:

A	B	Type	Score
CALR	THBS3	psi-mi:“MI:0915”(physical association)	0.560
DLST	THBS3	psi-mi:“MI:0915”(physical association)	0.560
THBS3	NEK7	psi-mi:“MI:0915”(physical association)	0.560
SDC1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
THBS3		psi-mi:“MI:0915”(physical association)	0.370
THBS3	APBB1	psi-mi:“MI:0914”(association)	0.350
FGG	ACOT7	psi-mi:“MI:0914”(association)	0.350

BioGRID (140): HSPD1 (Affinity Capture-MS), BBS2 (Affinity Capture-MS), CPS1 (Affinity Capture-MS), RFC1 (Affinity Capture-MS), SMG8 (Affinity Capture-MS), ASCC3 (Affinity Capture-MS), PC (Affinity Capture-MS), CCT7 (Affinity Capture-MS), RIC8B (Affinity Capture-MS), TRO (Affinity Capture-MS), GTPBP6 (Affinity Capture-MS), METTL13 (Affinity Capture-MS), CCZ1 (Affinity Capture-MS), NDUFA3 (Affinity Capture-MS), PKN2 (Affinity Capture-MS)

ESM2 similar proteins: A0A131MBU3, A1Z877, B5DFC9, G5EFD5, M9PE65, O02466, O18016, O76840, O77469, O88322, O97827, P10493, P13508, P14543, P14585, P35443, P41950, P41990, P49744, P49746, P51559, P98160, Q04833, Q05793, Q05895, Q06441, Q06561, Q17800, Q19617, Q1L8P7, Q20911, Q24247, Q27591, Q29RU4, Q3SWW8, Q6DI48, Q7QIQ6, Q80TS3, Q811M5, Q8JGW0

Diamond homologs: A0A1D0C023, A2ARV4, B3EWY9, B3NBB6, B4HVU2, B4PD96, B5DFC9, F1RRV3, O08523, O08710, O42182, O73775, O75095, O75197, O75443, O75581, O77469, O88322, O88572, P01130, P01131, P01266, P01267, P04233, P04441, P06882, P07522, P08460, P10247, P10493, P14543, P20063, P23142, P27590, P31226, P35442, P35443, P35444, P35445, P48960

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

142 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	121
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4150 predictions. Top by Δscore:

Variant	Effect	Δscore
1:155197505:AG:A	donor_gain	1.0000
1:155197534:T:TA	donor_gain	1.0000
1:155198408:CCAT:C	donor_gain	1.0000
1:155200459:T:TA	donor_gain	1.0000
1:155200465:T:TA	donor_gain	1.0000
1:155200482:T:TA	donor_gain	1.0000
1:155200486:T:TA	donor_gain	1.0000
1:155200611:C:CA	acceptor_loss	1.0000
1:155200612:T:C	acceptor_loss	1.0000
1:155200616:C:CT	acceptor_gain	1.0000
1:155201086:C:CA	donor_gain	1.0000
1:155201203:CA:C	acceptor_gain	1.0000
1:155201205:C:CC	acceptor_gain	1.0000
1:155201951:GCTCA:G	donor_loss	1.0000
1:155201952:CTCA:C	donor_loss	1.0000
1:155201954:CA:C	donor_loss	1.0000
1:155201955:A:AC	donor_gain	1.0000
1:155201955:A:AG	donor_loss	1.0000
1:155201956:C:CC	donor_gain	1.0000
1:155201956:CCA:C	donor_gain	1.0000
1:155201956:CCACA:C	donor_gain	1.0000
1:155203138:CTGG:C	acceptor_loss	1.0000
1:155203139:T:A	acceptor_loss	1.0000
1:155205314:GTA:G	acceptor_gain	1.0000
1:155205317:C:CC	acceptor_gain	1.0000
1:155207796:AC:A	donor_gain	1.0000
1:155207797:CC:C	donor_gain	1.0000
1:155197510:G:A	donor_gain	0.9900
1:155197534:TCC:T	donor_gain	0.9900
1:155197543:C:CT	donor_gain	0.9900

AlphaMissense

6358 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:155196014:A:G	W929R	1.000
1:155196014:A:T	W929R	1.000
1:155196027:T:A	Q924H	1.000
1:155196027:T:G	Q924H	1.000
1:155196031:G:A	S923F	1.000
1:155196032:A:G	S923P	1.000
1:155196033:G:C	F922L	1.000
1:155196033:G:T	F922L	1.000
1:155196035:A:G	F922L	1.000
1:155196036:G:C	C921W	1.000
1:155197100:C:A	W871C	1.000
1:155197100:C:G	W871C	1.000
1:155197102:A:G	W871R	1.000
1:155197102:A:T	W871R	1.000
1:155197163:C:A	W850C	1.000
1:155197163:C:G	W850C	1.000
1:155197165:A:G	W850R	1.000
1:155197165:A:T	W850R	1.000
1:155197467:A:G	L832P	1.000
1:155197511:C:A	W817C	1.000
1:155197511:C:G	W817C	1.000
1:155197532:C:A	K810N	1.000
1:155197532:C:G	K810N	1.000
1:155197537:A:G	W809R	1.000
1:155197537:A:T	W809R	1.000
1:155197593:T:A	D790V	1.000
1:155197593:T:C	D790G	1.000
1:155197593:T:G	D790A	1.000
1:155197594:C:G	D790H	1.000
1:155197596:T:A	D789V	1.000

dbSNP variants (sampled 300 via entrez): RS1000441255 (1:155209566 C>T), RS1000779176 (1:155195516 C>A), RS1001048297 (1:155208357 G>A), RS1001146257 (1:155195125 G>A), RS1001170447 (1:155210003 G>A), RS1001397487 (1:155208618 T>C), RS1001947023 (1:155207240 A>G), RS1002183499 (1:155196535 A>G), RS1002214316 (1:155196188 A>G), RS1002955122 (1:155205828 A>C), RS1003004372 (1:155205371 C>G), RS1003185129 (1:155198310 T>G), RS1003428556 (1:155198340 A>G), RS1003702993 (1:155205506 G>A), RS1004012499 (1:155203788 G>C)

Disease associations

OMIM: gene MIM:188062 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

24 associations (top):

Study	Trait	p-value
GCST003254_5	Urinary albumin-to-creatinine ratio in non-diabetics	9.000000e-06
GCST003255_9	Urinary albumin-to-creatinine ratio	7.000000e-06
GCST004131_70	Inflammatory bowel disease	6.000000e-08
GCST004132_44	Crohn’s disease	2.000000e-07
GCST006979_954	Heel bone mineral density	6.000000e-12
GCST007294_124	Body fat distribution (trunk fat ratio)	8.000000e-35
GCST007294_3	Body fat distribution (trunk fat ratio)	6.000000e-21
GCST007294_50	Body fat distribution (trunk fat ratio)	1.000000e-15
GCST007295_17	Body fat distribution (leg fat ratio)	3.000000e-13
GCST007295_37	Body fat distribution (leg fat ratio)	7.000000e-17
GCST007295_72	Body fat distribution (leg fat ratio)	1.000000e-28
GCST007536_1	Serum urea levels	4.000000e-09
GCST008707_1	Occipital lobe volume	1.000000e-07
GCST009649_3	Serum cancer antigen 15.3 levels	3.000000e-63
GCST009649_4	Serum cancer antigen 15.3 levels	1.000000e-14
GCST010696_19	Cortical thickness (min-P)	2.000000e-10
GCST010697_10	Cortical surface area (min-P)	3.000000e-10
GCST010698_59	Subcortical volume (min-P)	9.000000e-10
GCST010699_20	Brain morphology (min-P)	7.000000e-10
GCST010700_5	Cortical thickness (MOSTest)	8.000000e-17
GCST010701_66	Cortical surface area (MOSTest)	1.000000e-09
GCST010702_43	Subcortical volume (MOSTest)	3.000000e-10
GCST010703_253	Brain morphology (MOSTest)	4.000000e-14
GCST90002391_65	Mean corpuscular hemoglobin concentration	2.000000e-15

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007778	urinary albumin to creatinine ratio
EFO:0009270	heel bone mineral density
EFO:0004341	body fat distribution
EFO:0010585	cancer antigen 15.3 measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0004528	mean corpuscular hemoglobin concentration

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
Valproic Acid	affects expression, decreases expression, increases methylation	3
Arsenic	affects cotreatment, decreases expression, increases abundance	2
Dexamethasone	decreases expression, affects cotreatment	2
Silicon Dioxide	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
afuresertib	increases expression	1
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
benazol P	affects expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
Am 580	increases expression	1
CGP 52608	affects binding, increases reaction	1
ICG 001	increases expression	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Dasatinib	increases expression	1
Rosiglitazone	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Glyphosate	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Carbamazepine	affects expression	1
Chelating Agents	affects binding, increases expression	1
Cisplatin	increases expression, affects cotreatment	1
Copper	affects binding, increases expression	1
Doxorubicin	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0QZ	Ubigene HeLa THBS3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome